Pitavastatin Calcium

Brand name: Livalo

Rank #288 of 500 drugs by total cost

Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026

$40.8M

Total Cost

Share:

69,636

Total Claims

$40.8M

Total Cost

3,199

Prescribers

$587

Cost per Claim

3,677

Beneficiaries

128,513

30-Day Fills

$13K

Avg Cost/Provider

22

Avg Claims/Provider

Share of Medicare Part D Spending

0.01%

of total Medicare Part D spending

$40.8M of $275.65B

Top Prescribers by Cost

Top 10 prescribers of $40.8M total

🔎 Data Overview

👤

Average cost of $11,109 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Top Prescribers of Pitavastatin Calcium

#ProviderSpecialtyLocationClaimsCost
1Gary ReznikCardiologyLos Angeles, CA1,617$596K
2Afshine EmraniCardiologyTarzana, CA653$369K
3Anna MilsteinCardiologyLos Angeles, CA626$230K
4Zhengnan YinFamily PracticeHouston, TX238$209K
5Edwin YauFamily PracticeMonterey Park, CA515$189K
6Eddie LimInternal MedicineHonolulu, HI260$160K
7Don LeeInterventional CardiologyGlendale, CA299$154K
8Nathaniel LebowitzCardiologyFort Lee, NJ174$140K
9Lynn XuNurse PractitionerMonterey Park, CA259$131K
10Raveen AroraCardiologyAnaheim, CA175$120K
11Joyce YeungNurse PractitionerBrooklyn, NY192$113K
12Rui Er TengFamily PracticeBrooklyn, NY129$110K
13Vlad NusinovichInternal MedicineWest Hollywood, CA315$109K
14Kuocheng WangInternal MedicineNew York, NY239$106K
15Yili HuangCardiologyElmhurst, NY160$92K

Top prescribers ranked by total cost for this drug in 2023.

Related Drugs by Cost

#DrugTotal CostClaims
285Travoprost (Travoprost)$41.5M178,599
286Alendronate Sodium (Alendronate Sodium)$41.4M3,414,824
287Daptomycin (Daptomycin)$41.2M41,245
288Pitavastatin Calcium (Livalo)$40.8M69,636
289Bromfenac Sodium (Prolensa)$40.8M121,284
290Suvorexant (Belsomra)$40.7M87,327
291Atogepant (Qulipta)$40.7M32,955

Related Analysis

Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology